Physician profile
Mark E Quiring
NPI 1356343412
$2,148.92
in general payments reported to CMS, 2019-2025
20 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $42.92 · 2021: $54.95 · 2022: $126 · 2023: $68.59 · 2024: $436 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.26 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $603.36 | 2019 | |
| Boston Scientific Corporation | $500.10 | 2024-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter |
| Calyxo, INC. | $194.51 | 2025 | Cvac Aspiration System |
| Janssen Pharmaceuticals, INC | $152.20 | 2019 | |
| Glaxosmithkline, LLC. | $124.66 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $87.41 | 2019 | |
| Idorsia Pharmaceuticals US INC | $72.24 | 2022 | |
| Horizon Therapeutics Plc | $60.96 | 2019-2022 | |
| Dexcom, INC. | $52.27 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $48.03 | 2025 | Ozempic |
| Astrazeneca Pharmaceuticals Lp | $42.84 | 2020-2024 | Airsupra |
| Currax Pharmaceuticals LLC | $38.76 | 2021-2023 | Nexletol |
| Amgen INC. | $35.49 | 2024-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $33.24 | 2024-2025 | Voquezna |
| Pfizer INC. | $22.57 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $18.14 | 2020 | |
| Abbvie INC. | $16.85 | 2021 | |
| Exact Sciences Corporation | $16.79 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.68 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Quiring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.